Hong Kong Pharmaceutical Market Analysis

Hong Kong
Pharmaceutical
Market Analysis
A sample report on
Includes Market Size, Market Segmented by
Types and Key Competitors (Data forecasts
from 2023 – 2030F)
www.insights10.com

This report presents a strategic analysis of the Hong Kong
Pharmaceutical Market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Hong Kong Pharmaceutical Market , and offers
unmatched value, accuracy, and expert insights

3
A Sample Report on Hong Kong Pharmaceutical Market I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Pharmaceutical Overview 12-24
1.1. Overview
1.2. Hong Kong Overview
1.3. Economic Overview: Hong Kong
1.4. Pharmaceutical Market in Hong Kong
1.5. Healthcare Scenario in Hong Kong
1.6. Health Insurance Coverage: Hong Kong
1.7. Budget of the Government for Public Insurance
1.8. Mergers and Acquisitions
2. Market Size and Forecasting 25-30
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. Product
2.2.2. Type
2.2.3. Therapeutic category
3. Market Dynamics 31-35
3.1. Market Growth Drivers
3.1.1. Hong Kong Pharmaceutical Market Driver 1
3.1.2. Hong Kong Pharmaceutical Market Driver 2
3.2. Market Restraints
3.2.1. Hong Kong Pharmaceutical Market Restraint 1

6
Table of Content
CONTENT PG. NO.
4. Competitive Landscape 36-42
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Sino Biopharmaceutical limited
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)

7
Table of Content
CONTENT PG. NO.
4.2.2. Lee’s Pharmaceutical Holdings limited
4.2.2.2. Overview
4.2.3. Chong Kun Dang Pharmaceutical
4.2.3.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.4. Hoffmann- La Roche
4.2.4.2. Overview
4.2.5. Novartis
4.2.5.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.6. GlaxoSmithKline
4.2.6.1. Overview
4.2.7. Pfizer
4.2.7.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.8. Merck and co.
4.2.8.1. Overview
4.2.9. Sanofi
4.2.9.1. Overview

11
Table of Content
CONTENT PG. NO.
4.2.10. AstraZeneca
4.2.10.2. Overview
5. Reimbursement Scenario 43-47
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Nutritional Supplements
6. Methodology & Scope 48-75

Hong Kong Pharmaceutical Market
1. Pharmaceutical Market Overview

13
1.1 Statistics at a Glance: Pharmaceuticals in the world
Prevalence of Pharmaceuticals ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of Pharmaceutical, CAGR
and revenue , new technology, and other
details related to the topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Biotech
Segment is predicted to
account for 35 % of
spending globally in 2027
6147
Pharmaceutical products
were in active development
from phase 1 to regulatory
submission in 2022
Illustrative
$1.48 Tn
Revenue from global
pharmaceutical market in
2022
41,517
Plus pharmaceutical
companies are registered
in international directory of
pharmaceutical
companies 202222
Oncology
Is one of the largest
pharmaceutical segment
which accounted for $99.5 Bn
sales in 2022
United States
Is the largest
pharmaceutical market in
the world accounting for
47% of the total global
sales

14
1.1 Statistics at a Glance: Pharmaceutical in the World (continued)
North America
~ Market Size of
$XX Bn
Europe
~Revenue to reach
$XX Bn by 2027 Asia
-$XX Mn Market
Africa
~Market Size of
$XXBn
Illustrative
Hong Kong Market
~$xx Mn Market

15
1.2 Hong Kong Overview
7.37 Bn
Is the population of
Hong Kong, in 2022
45.3
Is the median age
in Hong Kong, in
2022
$429 Bn
Is the Gross
Domestic Product
(GDP) of Hong Kong
in 2022
$25,300
Per capita was the
amount of national
health expenditures in
2022
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
Illustrative

16
1.3 Economic Overview: Hong Kong
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Hong Kong, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Hong Kong, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
47.34
Female
52.66
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: Pharmaceutical in Hong Kong
Prevalence of Pharmaceutical
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of
Pharmaceutical in Hong Kong, new
technology, and other details related to
the topic in Hong Kong
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Cold and Cough
remedies
Accounted for the
highest revenue in
OTC pharmaceuticals
on Hong Kong in 2022
1218
Clinical trials were conducted
in Hong Kong in 2022 for
development of new
pharmaceuticals
$2.3 Bn
Hong Kong pharmaceutical
market size in 2021
32%
Revenue in OTC
pharmaceuticals market
in Hong Kong was
generated through online
sales in 2022
54.7%
Market share in Hong
Kong pharmaceutical
market was held by
proprietary medicines in
2019
$86.4 Mn
Worth pharmaceutical
products were exported from
Hong Kong to Macau in 2021
Illustrative

18
1.5 Healthcare Scenario in Hong Kong
Hong Kong Pharmaceutical Market: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

19
1.5 Healthcare Scenario in Hong Kong: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

20
1.6 Health Insurance Coverage: Hong Kong
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care
(1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

21
1.7 Budget of Hong Kong Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public
Insarance
$769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
As % Of GDP 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

22
1.8 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

23
1.8 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Collaboration $Xx Mn 2023
▪ Aim of the deal is advance life science innovation in Hong Kong
and the Greater Bay Area (GBA)
▪ The collaboration will focus on three key areas Policy shaping,
startup co incubation and health data sharing in ethical manner
▪ The long-term goal is to turn the GBA into a national leader in life
science and healthcare innovation, and setting an example the
rest of the country might follow in technology application and
registration.
Latest Deals In Hong Kong
Illustrative

2. Market Size and Forecasting

25
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
2.1 Market Size and Forecasts (Excel and Methodology)
Hong Kong Pharmaceutical Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the overall
Pharmaceutical market in Hong Kong,
which includes the market size, current
trends and other details related to the
topic
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Hong Kong Patient Size
(Bn)
0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Hong Kong Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Hong Kong Market Size
(Bn $)
61 74 84 87 91 95 99 106
Illustrative

26
2.2 Snapshot of Pharmaceutical Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Hong Kong Pharmaceutical Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Product
Branded
Generic
By Type
Prescription
OTC
By Therapeutic Category
Oncology
Cardiovascular
Diseases
Anti-infectives
Central Nervous
System Disorders
Metabolic Disorders
Gastrointestinal
Disorders
Respiratory Diseases
Others

27
Hong Kong Pharmaceutical Market Share, By Product (2022)
Branded
Generic
2.2.1 Market Segmentation: By Product
▪ Branded products are a significant
component of the overall Pharmaceutical
market in Hong Kong
▪ It has the maximum market share in Hong
Kong Pharmaceutical market with
approximately xx%
report
interest

28
Hong Kong Pharmaceutical Market Share, By Type (2022)
Prescription
OTC
2.2.2 Market Segmentation: By Type
▪ Prescription Products is a significant
component of the overall Pharmaceutical
market in Hong Kong
▪ It has the maximum market share in Hong
Kong Pharmaceutical market with
approximately xx%
report
interest

29
Hong Kong Pharmaceutical Market Share, By End User (2022)
Cardiovascular
diseases
Central nervous
system diseases
Oncology
Anti-infectives
Metabolic
disorders
Gastrointestinal
disorders
Respiratory
diseases
2.2.3 Market Segmentation: By End User
▪ Cardiovascular diseases, central nervous
system disorders and oncology have the
maximum market share in Hong Kong
Pharmaceutical market with approximately
xx%
report
interest

3. Market Dynamics

31
Increase in Export of Pharmaceutical
Products
▪ Increase in export of pharmaceutical products to other countries
like China and Macau acts as a market growth driver for Hong
Kong pharmaceutical market
▪ $86.4 Mn pharmaceutical products were exported from Hong
Kong to Macau in 2021
▪ Development of Guangdong-Hong Kong-Macao Greater Bay
Area (GBA) where
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to
the topic or subject matter of interest
Illustrative
2010 2022 2030
3.1 Market growth drivers (continued)
3.1.1 Increase in export of pharmaceutical products from Hong Kong to bordering countries like China and Macau
acts as a market growth driver for Hong Kong pharmaceutical market

32
▪ Geriatric population make up a significant component of the total
population of Hong Kong which is also projected to increase
significantly in the coming years
▪ Geriatric individuals suffer from chronic diseases which acts as
market growth driver for Pharmaceutical market in Hong Kong
▪ Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and analysis
that will be presented in the final report
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to
the topic or subject matter of interest
Illustrative
2010 2022 2030
3.1 Market growth drivers (continued)
3.1.2 Growing geriatric population in Hong Kong with over 1.48 Mn population above 65 years in 2022 which is
projected to reach above 1.6 Mn in 2050
Increase in Geriatric Population in Hong
Kong

33
3.2 Market restraints
3.2.1 Prevalence of
Traditional Chinese
Medicines in Hong Kong
▪ Traditional Chinese medicines
are prevalent and highly
accepted in Hong Kong
▪ Drugs in Hong Kong are divided
into two main categories of
Chinese medicines and western
medicines
▪ This factor thus acts as a market
growth restraint for acceptance
of newly developed
pharmaceuticals in Hong Kong
3.2.2 Regulatory challenges
in approval of new drugs
▪ Presence of strict regulatory
guidelines in registration and
approval of pharmaceuticals acts
as a market growth restraint
▪ Drug office of Department of
Health, government of Hong
Kong is responsible for
regulating the safety and efficacy
of pharmaceuticals in Hong Kong
3.2.3 High costs of research
and development of
pharmaceutical products in
Hong Kong
▪ High costs of Research and
development of development of
pharmaceutical products are
involved in Hong Kong
▪ Pharmaceutical companies are
thus shifting their Research and
development plants in China
thus acting as a market growth
restraint to Hong Kong
pharmaceutical market
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

4. Competitive Landscape

35
4.1 Major Market Share
XX
Other
▪ Some of the top companies in Hong Kong
Pharmaceutical Market based on revenue
and market share include
interest
Revenue of Major Players in Hong Kong Pharmaceutical Market ($
Mn)
Illustrative

36
4.2 Key Company Profile
Key Notes
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
Illustrative
1 Sino Biopharmaceutical
3
Chong Kun Dang
Pharmaceutical
5 Novartis
7 Pfizer
9 Sanofi
2
Lee's Pharmaceutical
Holdings Limited
4 Hoffmann-La Roche
6 GlaxoSmithKline
8 Merck & Co.
AstraZeneca
10

37
4.2.1 SINO BIOPHARMACEUTICAL LIMITED
Founded in: 2000
HQ: Beijing, China
Type: Private
Revenue: $3760 Bn
Website:
www.sinobiopharm.com
▪ Sino Biopharmaceutical limited is currently the second largest
pharma company in China in terms of revenue
▪ It has above 25000 employees in 2021 and its 40 innovate drug
candidates have potential to launch by 2040
▪ Sino Biopharmaceutical limited has more than 1400 invention
patents and employees above 2700 individuals in R and D team
▪ Sino Biopharmaceutical limited mission is science for a healthier
world
Solutions offered by Company
➢ Diagnostics
➢ Pharmaceuticals
➢ Research and development
➢ Clinical Trials
Oncology Surgery
Hepatology Analgesic
Respiratory Others
Therapeutic
Portfolio
Recent Activity / Press Coverage
On February 20, Sino Biopharmaceutical announced that Liamprost tablet (brand name:
Kelitone ®), a treatment for lumbar spinal stenosis developed by its subsidiary of Beijing Tide,
has been approved by the National Medical Products Administration (NMPA)
In March 2023, invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of
Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing
pipeline of innovative products, announced that it has successfully completed the acquisition
of F-star Therapeutics, Inc.
Illustrative

38
Partnerships Ecosystem
Illustrative

39
4.2.1 DOCTOR ANYWHERE
Company Type
Amount /
Shares
Year Key Pointers
Acquisition $161 Mn March 2023
▪ invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned
subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”)
with an advancing pipeline of innovative products, has
successfully completed the acquisition of F-star Therapeutics,
Inc. (“F-star”) a clinical-stage biopharmaceutical company
pioneering bispecific antibodies in immunotherapy
▪ invoX will now be able to develop next generation
immunotherapies to treat cancer patients through a leading and
differentiated bispecific antibody platform
Collaboration --
January 2020
▪ Ambrx Inc., a clinical-stage biopharmaceutical company focused
on the development of next generation biologics using an
expanded genetic code and Sino Biopharmaceutical Limited
(1177.HK), a leading Chinese pharmaceutical company with a
large number of medical products covering multiple therapeutic
areas, announced a joint collaboration to develop two products
enabled by Ambrx's unique non-natural amino acid incorporation
technology platforms.
Latest Deals - Mergers and Acquisitions
Illustrative

40
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

41
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

42
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

43
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

44
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

46
5.1 Reimbursement Regulation in Hong Kong
The reimbursement scenario in Hong Kong nutritional supplement market is
complex and can vary depending on the specific treatment, setting of care, and
insurance coverage. Here are some key points to consider:
▪ Public Insurance:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Population
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

47
5.1 Reimbursement Regulation in Hong Kong (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

48
5.1 Reimbursement Regulation in Hong Kong (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Healthcare Services
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, Pharmaceutical, analytics and
data science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Pharmaceutical with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Hong Kong Pharmaceutical Market Analysis

Recommended

Recommended

More Related Content

Similar to Hong Kong Pharmaceutical Market Analysis

Similar to Hong Kong Pharmaceutical Market Analysis (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (19)

Hong Kong Pharmaceutical Market Analysis